- Home
- KORE vs PRLD Comparison
KORE vs PRLD Comparison
Compare KORE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KORE
- PRLD
- Stock Information
- Founded
- KORE 2003
- PRLD 2016
- Country
- KORE United States
- PRLD United States
- Employees
- KORE N/A
- PRLD N/A
- Industry
- KORE Telecommunications Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- KORE Consumer Discretionary
- PRLD Health Care
- Exchange
- KORE Nasdaq
- PRLD Nasdaq
- Market Cap
- KORE 45.0M
- PRLD 50.1M
- IPO Year
- KORE N/A
- PRLD 2020
- Fundamental
- Price
- KORE $2.30
- PRLD $0.88
- Analyst Decision
- KORE Hold
- PRLD Strong Buy
- Analyst Count
- KORE 2
- PRLD 2
- Target Price
- KORE $2.75
- PRLD $4.50
- AVG Volume (30 Days)
- KORE 15.9K
- PRLD 165.9K
- Earning Date
- KORE 08-14-2025
- PRLD 08-11-2025
- Dividend Yield
- KORE N/A
- PRLD N/A
- EPS Growth
- KORE N/A
- PRLD N/A
- EPS
- KORE N/A
- PRLD N/A
- Revenue
- KORE $282,254,000.00
- PRLD $7,000,000.00
- Revenue This Year
- KORE $4.66
- PRLD N/A
- Revenue Next Year
- KORE $6.71
- PRLD N/A
- P/E Ratio
- KORE N/A
- PRLD N/A
- Revenue Growth
- KORE N/A
- PRLD N/A
- 52 Week Low
- KORE $1.10
- PRLD $0.61
- 52 Week High
- KORE $4.88
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- KORE 44.65
- PRLD 48.33
- Support Level
- KORE $2.22
- PRLD $0.85
- Resistance Level
- KORE $2.49
- PRLD $1.25
- Average True Range (ATR)
- KORE 0.19
- PRLD 0.10
- MACD
- KORE -0.02
- PRLD -0.02
- Stochastic Oscillator
- KORE 12.13
- PRLD 18.52
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.